Cryopreserved Chorionic Membrane With Viable Cells for Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing commercial wound healing products, such as Apligraf and Dermagraft, do not provide optimal cellular compositions and ratios of factors for efficient wound healing, lacking key components like mesenchymal stem cells, Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), adiponectin, and a favorable protease-to-protease inhibitor ratio, leading to sub-optimal wound healing outcomes.
Innovation Solution
Development of a placental product comprising an immunocompatible chorionic membrane with cryopreserved viable native therapeutic cells and factors, selectively depleted of immunogenic cells, and containing factors like IGFBP-1, adiponectin, α2-macroglobulin, and bFGF, with a regulated MMP-9:TIMP1 ratio, to promote wound healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fresh chorionic membrane is used for wound healing therapy, then cell viability is high (100%), but there is increased risk of disease transmission
Solution Approach 1:
The patent applies parameter changes by transitioning the chorionic membrane from fresh to frozen state, changing the temperature parameter from physiological conditions to sub-zero storage conditions. This parameter change preserves cell viability while eliminating disease transmission risk through freezing, which inactivates pathogens while maintaining therapeutic cell functionality.
Solution Approach 2:
The patent implements preliminary action by freezing the chorionic membrane in advance before clinical use. This preliminary freezing process pre-eliminates disease transmission risks while preserving cell viability, allowing the product to be stored and deployed when needed without compromising safety or efficacy.
2Reliability
If chorionic membrane is used for wound healing, then it provides therapeutic factors, but it exhibits immunogenicity
Solution Approach 1:
The patent applies parameter changes by using controlled freezing and thawing parameters to selectively affect different cell types. The freezing process at specific temperatures and rates induces differential stress responses that eliminate immunogenic cells while preserving therapeutic cells, thereby reducing immunogenicity while maintaining therapeutic efficacy.
Solution Approach 2:
The patent implements taking out by selectively removing or eliminating immunogenic components from the chorionic membrane through the freezing process. The method extracts or eliminates the harmful immunogenic elements while retaining the beneficial therapeutic factors and cells needed for wound healing.
3Stability of the object's composition
If existing commercial products like Apligraf and Dermagraft are used, then they provide structured cellular composition, but they lack key factors like IGFBP-1, adiponectin, and favorable protease-to-protease inhibitor ratio
Solution Approach 1:
The patent applies composite materials by creating a chorionic membrane product that combines multiple therapeutic elements in their native proportions. The frozen chorionic membrane naturally contains a composite of therapeutic cells, growth factors, cytokines, and protease-protease inhibitor pairs in authentic ratios, mimicking the native tissue composition that commercial products fail to replicate.
Solution Approach 2:
The patent implements self-service by utilizing the chorionic membrane's own native composition rather than attempting to reconstruct it artificially. The frozen chorionic membrane naturally provides the complete array of therapeutic factors, cells, and molecular ratios needed for wound healing without requiring external addition or artificial assembly, thereby self-providing all necessary therapeutic components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The placental product enhances wound healing by providing a native cellular composition that mimics natural tissue, improving healing processes through enhanced cell migration, vascularization, and factor secretion, while minimizing immunogenicity and maintaining factor viability.
Implementation Method 1
comprising an immunocompatible chorionic membrane in a cryopreservation medium (optionally cryopreserved) and viable native therapeutic cells and native therapeutic factors
Data Source
AI summary
Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.